Entering text into the input field will update the search result below

Belite Bio initiated with a Buy at Benchmark

Jul. 01, 2022 12:21 PM ETBLTEBy: Pranav Ghumatkar, SA News Editor
  • Benchmark analyst Bruce Jackson initiated coverage of Belite Bio (BLTE) with a Buy rating and $57 price target.
  • The clinical-stage biopharmaceutical company's lead asset is LBS-008, which is designed to slow retinal degeneration in dry Age-Related Macular Degeneration, or dry AMD, and autosomal recessive

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.